Company Presentation

July 2017
AMW - A Specialty Pharmaceuticals Developer and Manufacturer

- Founded in 2008
- Located in Warngau, Germany, 40 km south of Munich
- Approx. 100 employees, thereof 11 trainees
- Focus on advanced drug delivery systems, e.g. transdermal and transmucosal delivery systems (passive and active control) and parenteral (intracranial, subcutaneous, ...) biodegradable delivery systems
- Core areas: hormone and pain therapy, oncology and neurology
- Funded by private and institutional investors, founders and management, approx. 33% each
Manufacturing Patches

Market Perspectives:
• Worldwide transdermal delivery market is expected to reach more than 40 billion US$ in 2018 (1)

• There is only a very limited number of players in the market being able to develop and manufacture these transdermal products

Production Facility of AMW GmbH:
• clean-room environment Class D* with capacity for industrial mass production
• sufficient space for future expansion at the Warngau site

Manufacturing Biodegradable Implants

Market Perspectives:
- Worldwide biodegradable drug delivery implant market was 11.6 billion US$ in 2011 and is expected to exceed 21 billion US$ by 2018 (2)

- AMW is the second biggest manufacturer of these implants worldwide and so far the only manufacturer of generic Goserelin implants

Production Facility of AMW GmbH:
- clean-room environment Class C with capacity for industrial mass production up to 400,000 per year
- sufficient space for future expansion at the Warngau site with new production plant - Expansion of production site midst of 2017 -

(2) http://www.transparencymarketresearch.com/pressrelease/implantable-drug-delivery-devices.htm
Certifications

✓ Manufacturing Authorization for transdermal systems and implants with active substances

✓ GMP Certificate

✓ Certified in accordance with DIN EN ISO 13485 for medical devices

✓ Permission for handling narcotic substances
Main Areas of Activity

Proprietary products

- Approved products: Buprenorphine and Rivastigmin patches
- Under development: Rotigotine and Anastrozole patches

Contract Development Services

- Approved products: Goserelin biodegradable implants
- Under development: Leuprorelin, Exenatide, and MAB implants

Customized products, i.e. fertility control patch, hypertension patch, scar patch

- Approved products: Buprenorphine and Rivastigmin patches
- Under development: Rotigotine and Anastrozole patches

- Approved products: Goserelin biodegradable implants
- Under development: Leuprorelin, Exenatide, and MAB implants

- Customized products, i.e. fertility control patch, hypertension patch, scar patch
Endomedica GmbH - R&D -

• since 2014 Endomedica GmbH in Halle/Saale (Saxonia-Anhalt)
• subsidiary of AMW GmbH
• Research and Development (R&D) of medicinal products and medical devices for transdermal application
• Permission for handling narcotic substances
• new laboratory capacities since 2016
Active Release Transdermal Patch

- Currently exclusively focussed on the development of electronically controlled transdermal patch
  - Patented technology
  - Feasibility study successfully completed
  - Pilot study planned for 2017
  - alternative transdermal system instead of iontophoretic patch without painful side effects of skin irritation
Endomedica GmbH - R&D -

• Existing Cooperations:
  
  ![Fraunhofer IMS](image)
  Fraunhofer Institute for Microelectronic Circuits and Systems; Duisburg

  ![Fraunhofer ENAS](image)
  Fraunhofer Institute for Electronic Nano Systems; Chemnitz

  ![Renata Batteries](image)
  Renata SA; Itingen / Switzerland

• Target Cooperation:
  
  ![Fraunhofer IWS](image)
  Fraunhofer-Institute for Material and Beam Technology; Dresden
Contact

Research & Development:
Dr. Wilfried Fischer
Managing Director

Business Development:
Thomas Ohlenbostel
Head of BD
t.ohlenbostel@a-m-w.eu
Tel.: +49 8024 470 999 80

www.a-m-w.eu/en/

Dr. Sebastian Luci
Endomedica GmbH
Weinbergweg 23
D-06120 Halle/Saale
Tel: +49(0)345/13142760 / -61
E-Mail: info@endomedica.de

www.endomedica.de